<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302870</url>
  </required_header>
  <id_info>
    <org_study_id>AC18082</org_study_id>
    <nct_id>NCT04302870</nct_id>
  </id_info>
  <brief_title>Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial</brief_title>
  <acronym>MND-SMART</acronym>
  <official_title>Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      MND-SMART is investigating whether selected drugs can slow down the progression of motor&#xD;
      neurone disease (MND) and improve survival.&#xD;
&#xD;
      The study is 'multi-arm' meaning more than one treatment will be tested at the same time. In&#xD;
      the first instance the trial will have 3 arms; drug 1, drug 2 and placebo (dummy drug). This&#xD;
      allows the evaluation of drug 1 versus placebo and separately drug 2 versus placebo.&#xD;
      Participants will be randomly allocated to either drug 1, drug 2 or placebo. Medicines being&#xD;
      tested are already approved for use in other conditions.&#xD;
&#xD;
      MND-SMART has an 'adaptive' design. This means medicines being studied can change according&#xD;
      to emerging results. Treatments shown to be ineffective can be dropped and new drugs can be&#xD;
      added over the duration of the study. This will allow many treatments, over time, to be&#xD;
      efficiently and definitively evaluated.&#xD;
&#xD;
      The first medicines being tested have been selected following a rigorous process involving a&#xD;
      systematic, unbiased, and comprehensive review of past clinical trials data, as well as&#xD;
      information from pre-clinical research (studies in laboratories), for MND and other related&#xD;
      neurodegenerative disorders. Drugs have been ranked for inclusion in MND-SMART by a group of&#xD;
      independent MND experts according to set criteria. These include consideration of how the&#xD;
      drugs work, their safety profiles, and the quality of previous studies.&#xD;
&#xD;
      New drugs will be selected for investigation in MND-SMART based on continuous review of&#xD;
      constantly updated scientific evidence as well as findings from state-of-the-art human stem&#xD;
      cell based drug discovery platforms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in decline of ALS-FRS(R) over 18months</measure>
    <time_frame>18 months</time_frame>
    <description>Co-primary outcome measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>18 months</time_frame>
    <description>Co-primary outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognition and behaviour</measure>
    <time_frame>18 months</time_frame>
    <description>Using Edinburgh Cognitive and Behavioural ALS Screen (ECAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function - Forced vital capacity</measure>
    <time_frame>18 months</time_frame>
    <description>Change in FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>King's ALS Clinical stage</measure>
    <time_frame>18 months</time_frame>
    <description>Time to reach King's stage IV, scale range I - V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in anxiety and depression</measure>
    <time_frame>18 months</time_frame>
    <description>Measured using the hospital anxiety and depression scale (HADS), scale range 0 - 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life</measure>
    <time_frame>18 months</time_frame>
    <description>Measured using EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of IMPs</measure>
    <time_frame>18 months</time_frame>
    <description>Measured using adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function - Sniff nasal inspiratory pressure</measure>
    <time_frame>18 months</time_frame>
    <description>Change in SNIP</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Motor Neuron Disease, Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trazodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine Hydrochloride Oral Solution</intervention_name>
    <description>Memantine hydrocholoride taken once daily</description>
    <arm_group_label>Memantine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone Hydrochloride oral solution</intervention_name>
    <description>Trazodone Hydrochloride taken once daily</description>
    <arm_group_label>Trazodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral solution</intervention_name>
    <description>Placebo taken once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of MND (including the following subtypes: ALS by El Escorial&#xD;
             Criteria (possible, probable, and definite), Primary Lateral Sclerosis, and&#xD;
             Progressive Muscular Atrophy)&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
          -  Women of childbearing potential according to Clinical Trials Facilitation and&#xD;
             Coordination Group (CTFG) guidelines must have a negative pregnancy test within 7 days&#xD;
             prior to, or at, the baseline visit&#xD;
&#xD;
          -  Women of childbearing potential and fertile men must be using an appropriate method of&#xD;
             contraception to avoid any unlikely teratogenic effects of the selected drugs from&#xD;
             time of consent, to 4 weeks after treatment inclusive&#xD;
&#xD;
          -  Willing and able to comply with the trial protocol and ability to understand and&#xD;
             complete questionnaires&#xD;
&#xD;
          -  Written informed consent (this can be signed by a proxy in the case of limb&#xD;
             dysfunction)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with Frontotemporal Dementia (FTD-MND) or any other significant&#xD;
             psychiatric disorder that prevents informed consent being given.&#xD;
&#xD;
          -  Patients in the manic phase of bipolar disorder.&#xD;
&#xD;
          -  Alcoholism (self-reported)&#xD;
&#xD;
          -  Active suicide ideation assessed using the Columbia-Suicide Severity Rating Scale&#xD;
&#xD;
          -  On concurrent investigational medication (including biological therapy)&#xD;
&#xD;
          -  Known hypersensitivity, including hereditary fructose intolerance, or adverse reaction&#xD;
             to the active substances and their excipients (SPCs section 6.1) or any past medical&#xD;
             history contraindicating use of any of the IMPs&#xD;
&#xD;
          -  Pregnancy or breast-feeding females&#xD;
&#xD;
          -  If ALT, ALP, bilirubin or GGT &gt;3 times the upper limit of normal.&#xD;
&#xD;
          -  If creatinine clearance (creatinine clearance or eGFR) &lt;30 ml/min.&#xD;
&#xD;
          -  If TSH &lt;0.2mU/l (if possible to test free T4, then Serum free T4 &gt;25pmol/l)&#xD;
&#xD;
          -  If corrected QT interval on 12 lead ECG &gt;450 ms&#xD;
&#xD;
          -  Patient's diagnosed with ventricular arrhythmias, significant heart block (at the&#xD;
             investigator's discretion) or in the immediate recovery period after myocardial&#xD;
             infarction (&lt; 6 weeks).&#xD;
&#xD;
          -  Already taking any of the IMPs in this protocol&#xD;
&#xD;
          -  Patient's contraindicated to any of the IMPs according to SPC section 4.3&#xD;
&#xD;
          -  Taking a medication that interacts with the active substances and their excipients&#xD;
             according to the SPCs, including but not limited to; Dextromethorphan, Amantadine;&#xD;
             Ketamine, Monoamineoxidase inhibitors ((MAOIs), Rasagiline, Selegiline, Safinamide,&#xD;
             Tranylcypromine, Phenelzine, Isocarboxazid, Moclobemide).&#xD;
&#xD;
          -  Patients who the PI considers will not be able to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Chandran</last_name>
    <role>Study Director</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Professor Chandran</last_name>
    <phone>0131 465 9612</phone>
    <email>siddharthan.chandran@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rachel Dakin</last_name>
    <phone>0131 465 9612</phone>
    <email>rachel.dakin@Ed.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Callum Duncan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre , Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Morrison</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anne Rowling Regenerative Neurology Clinic</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Newton</last_name>
      <phone>0131 242 7985</phone>
      <email>loth.mndsmart@nhslothian.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Harrower</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Gorrie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Highland Clinical Research Facility, Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Carod Artal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Facility Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisham Hamdalla</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research Facility University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashwin Pinto</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Trazodone</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

